RecommendationOffer alternative pharmacological treatment (a prostaglandin analogue, beta-blocker, carbonic anhydrase inhibitor or sympathomimetic) to people with OHT or suspected COAG and high IOP who are intolerant of the current medication.
Relative values of different outcomesThe surrogate outcome is IOP reduction which in turn reduces the risk of future conversion to COAG in people with elevated IOP. Intolerance to one medication may require use of an alternative provided costs are broadly similar.
Trade off between clinical benefits and harmsSide effects of topical glaucoma medications may cause significant morbidity for patients. Intolerance to medications is likely to lead to poor persistence.
Economic considerationsBeta-blockers are cost-effective for patients with IOP 21–32 mmHg, CCT <555 μm who cannot be treated with PGA. PGA are cost-effective for patients with IOP 25 – 32 mmHg, CCT 555 – 590 μm who cannot be treated with BB only up to the age of 60.
Quality of evidenceThere is no direct clinical evidence.
The economic evidence has minor limitations and direct applicability.
Other considerationsNone

From: 7, Treatment of ocular hypertension and suspected chronic open angle glaucoma

Cover of Glaucoma
Glaucoma: Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension.
NICE Clinical Guidelines, No. 85.
National Collaborating Centre for Acute Care (UK).
Copyright © 2009, National Collaborating Centre for Acute Care.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Collaborating Centre for Acute Care to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.